AnorMED Closes $34,500,000 Bought Deal Financing
December 8, 2005
For Immediate Release: December 08, 2005
Vancouver, British Columbia – AnorMED Inc. (AMEX:AOM; TSX:AOM) announced today that it has successfully closed its offering of 8,625,000 Common Shares for gross proceeds of $34,500,000 in connection with the previously announced agreement (the “Underwriting Agreement”) with an underwriting syndicate co-led by Raymond James Ltd. and BMO Nesbitt Burns Inc., and including CIBC World Markets Inc. and Canaccord Capital Corporation. The underwriting syndicate agreed to purchase 6,250,000 Common Shares from AnorMED, on a bought deal basis, and sell to the public at a price of $4.00 per Common Share (the “Issue Price”), representing an aggregate issue amount of $25,000,000. As well, the underwriters have exercised their option under the Underwriting Agreement to purchase an additional 1,250,000 Common Shares at the Issue Price for further gross proceeds of $5,000,000 and have exercised their over-allotment option under the Underwriting Agreement, to purchase an additional 1,125,000 Common Shares at the Issue Price for further gross proceeds of $4,500,000. As of December 8, 2005, after the closing, the Company has 40,501,692 Common Shares issued and outstanding.
THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY THE SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION.
THE SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933.
AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. The Company has four products in clinical development and a research program focused on a novel class of compounds that target specific chemokine receptors known to be involved in a variety of diseases. Additional information on AnorMED Inc. is available on the Company’s website www.anormed.com.
Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors include, but are not limited to, the Company’s need for additional funding, the Company’s expectations as to the use of proceeds from the offering and other risk factors associated with the Company’s business contained in the Company’s Final Short Form Prospectus filed with securities regulatory authorities and dated December 1, 2005. The Company does not expect to update any forward-looking statements as conditions change.
